Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
14 mars 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
11 mars 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7-Directed Molecular Glue Degrader
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
31 janv. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
08 janv. 2024 07h15 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
21 nov. 2023 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
07 nov. 2023 10h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
27 oct. 2023 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
26 oct. 2023 16h30 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules